Health Care & Life Sciences » Pharmaceuticals | Hybio Pharmaceutical Co. Ltd.

Hybio Pharmaceutical Co. Ltd.

Hybio Pharmaceutical Co. Ltd.
Stock Exchange Shenzhen Stock Exchange
EPS
CNY0.43
Market Cap
CNY8.28 B
Shares Outstanding
571.46 M
Public Float
413.48 M

Profile

Address
4/F, Hybio Biomedical Park Office
Shenzhen Guangdong 518057
China
Employees -
Website http://www.hybio.com.cn
Updated 07/08/2019
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet.

Financials

View All

Feng Chun He
Chairman-Supervisory Board
Shao Gui Zeng
Chairman